Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials

Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questions related to designing platform trials—such as the impact of decision rules, sharing of information across cohorts, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Elias Laurin, Mesenbrink, Peter, Dunger‐Baldauf, Cornelia, Glimm, Ekkehard, Li, Yuhan, König, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Main Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304586/
https://www.ncbi.nlm.nih.gov/pubmed/35102685
http://dx.doi.org/10.1002/pst.2194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304586/
https://www.ncbi.nlm.nih.gov/pubmed/35102685
http://dx.doi.org/10.1002/pst.2194

Ejemplares similares